CHINA PHARMA HOLDINGS, INC.
CPHI · XNYSCIK 1106644fmd_0R0DPQ681G55D398BMGYPAZ6VYManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2010 to Jun 30, 2026, 65 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 16 | 13 | 12 | 11 | 11 | 10 | 8 | 7 | 5 | 4 |
| Cost of revenue | 12 | 11 | 10 | 9 | 9 | 9 | 9 | 7 | 7 | 4 |
| Gross profit | 3 | 2 | 2 | 1 | 2 | 0 | (0) | (0) | (2) | (0) |
| Research and development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total operating expenses | 12 | 21 | 12 | 22 | 5 | 3 | 3 | 2 | 3 | 3 |
| Operating income | (8) | (19) | (10) | (20) | (3) | (3) | (4) | (3) | (5) | (3) |
| Interest expense | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | – | – |
| Other non-operating income (expense) | (1) | (0) | (0) | (0) | (0) | (1) | (0) | (0) | (0) | 0 |
| Income before taxes | (9) | (19) | (11) | (21) | (3) | (3) | (4) | (3) | (5) | (3) |
| Income tax expense | 0 | 0 | (0) | – | – | – | – | – | – | – |
| Net income from continuing operations | (9) | (19) | (11) | – | – | – | – | – | – | – |
| Net income | (9) | (19) | (11) | (21) | (3) | (3) | (4) | (3) | (5) | (3) |